Illuminating the Future for Cancer Patients
Solixia is an early-stage life science company formed to develop better treatment options for cancer. Our vision is to provide hope for patients suffering from metastatic or late-stage disease.
We are pioneering the field of radioimmunotherapy (RAIT) in which radioactive compounds are injected into a patient for the purpose of destroying tumors.
Our lead drug candidate, SLX-804, is a treatment for ovarian cancer, a disease characterized by high mortality.